Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AST2303 in Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06955988Phase 1Recruiting
- Sponsor
- Allist Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ABK3376 in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Allist Pharmaceuticals. Primary endpoints: Adverse Event up to 2 years, Serious Adverse Event up to 2 years and 6 more. Started Mar 2025; status: recruiting.
02
Drugs
ABK3376
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06955988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955988.